miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1

Li, Bingshou; Liu, Lin; Li, Xiaoming; Wu, Lingtong

doi:10.1016/j.bbrc.2015.06.169

Cited by 62 publications

(39 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression level of miR-1269a in HCC patients without portal vein tumor embolus was reduced72. In addition, the low expression of miR-125a-5p, miR-128-3p, miR-137, miR-185-5p, miR-188-5p, miR-26a-5p, miR-503-5p and miR-744-5p were detected in HCC tissues compared with their non-tumor livers and were involved in the multi-step processes35363773747576. There were six circulating prognostic biomarker miRNAs reported to be associated with tissue invasion and metastasis, including miR-122-5p, miR-17-5p, miR-182-5p, miR-21-5p, miR-24-3p and miR-331-3p, all of them were up-regulated in the group with low survival rate5661637778.…”

Section: Resultsmentioning

confidence: 99%

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Shen

Lin

Yuan

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Hepatocellular Carcinoma (HCC) is one of the most common malignant tumors with high incidence and mortality rate. Precision and effective biomarkers are therefore urgently needed for the early diagnosis and prognostic estimation. MicroRNAs (miRNAs) are important regulators which play functions in various cellular processes and biological activities. Accumulating evidence indicated that the abnormal expression of miRNAs are closely associated with HCC initiation and progression. Recently, many biomarker miRNAs for HCC have been identified from blood or tissues samples, however, the universality and specificity on clinicopathological features of them are less investigated. In this review, we comprehensively surveyed and compared the diagnostic, prognostic, and therapeutic roles of HCC biomarker miRNAs in blood and tissues based on the cancer hallmarks, etiological factors as well as ethnic groups, which will be helpful to the understanding of the pathogenesis of biomarker miRNAs in HCC development and further provide accurate clinical decisions for HCC diagnosis and treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Shen

Lin

Yuan

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Functional assays demonstrated that miR-503 suppresses EMT in GC cells by downregulating fibronectin, vimentin, N-cadherin, and SNAIL protein levels 8. Similarly, miR-503 was reported to inhibit the growth and invasiveness of prostate cancer, hepatocellular carcinoma, and breast cancer by downregulating the expression of RNF31,27 PRMT1,28 and CCND1,29 respectively. In addition, overexpression of miR-503 sensitized human GC cell lines to cisplatin by targeting IGF1R and BCL2 9.…”

Section: Discussionmentioning

confidence: 98%

Decreased miR-503 expression in gastric cancer is inversely correlated with serum carcinoembryonic antigen and acts as a potential prognostic and diagnostic biomarker

Wu¹,

Cao²,

Huang³

et al. 2016

OTT

View full text Add to dashboard Cite

BackgroundAltered expression of miR-503 has been linked to human carcinogenesis. In this present study, we aimed to detect the potential for miR-503 as a novel biomarker for gastric cancer (GC) patients.Materials and methodsThe relative mRNA level of miR-503 in serum and tissue of 68 GC patients and serum of 32 healthy volunteers was determined by real-time reverse transcription quantitative polymerase chain reaction.ResultsThe miR-503 level was significantly lower in the tissue and serum of GC than their counterparts (all P<0.01). Downregulation of miR-503 was found to be corrected with more aggressive tumor. Patients in the high-miR-503 group showed significantly better overall survival compared to the low-miR-503 group (P=0.021). The serum miR-503 level in GC was inversely correlated with carcinoembryonic antigen (CEA) (r=−0.624, P<0.001). Furthermore, the area under the receiver operating characteristic curve for miR-503 discriminating GC patients from healthy individuals was 0.889 (P=0.006), with a sensitivity of 96.8% and a specificity of 79.4%, higher than that of CEA (area under the receiver operating characteristic curve =0.681, P=0.048).ConclusionThe present study suggests that the expression level of miR-503 may serve as prognostic and diagnostic biomarker for GC.

show abstract

“…Recent reports have revealed the relationship between various cancers and PRMT1, which is overexpressed in breast cancer, bladder cancer and lung cancer [17][18][19][20].. Notably, PRMT1 was recently reported to be upregulated through miR-503 in HCC [21], and PRMT1 may promote the proliferation and metastasis of HCC cells in vitro [13]. However, these reports did not provide enough evidence, such as in vivo experiments, to prove this role of PRMT1 and the underlying mechanism in HCC.…”

Section: Discussionmentioning

confidence: 99%

PRMT1 Promoted HCC Growth and Metastasis In Vitro and In Vivo via Activating the STAT3 Signalling Pathway

Zhang

Jiang

Zhong

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Although it has been widely accepted that protein arginine methyltransferase 1 (PRMT1) is a cancer-promoting gene in various cancers, the mechanism of PRMT1 in hepatocellular carcinoma (HCC) requires more exploration. This study aimed to investigate the role of PRMT1 in HCC growth and metastasis. Methods: We compared PRMT1 expression and clinicopathological characteristics using paired HCC and adjacent noncancerous liver tissues from 210 patients and immunohistochemistry analyses. Cell proliferation, colony formation and migration were determined in HCC cell lines with PRMT1 overexpression or downregulation through MTT, crystal violet and Boyden chamber assays. Tumour growth was monitored in a xenograft model, and intrahepatic metastasis models were established. Results: PRMT1 expression was greatly increased in clinical HCC samples and strongly associated with poor prognosis and recurrence; PRMT1 expression was also positively correlated with microvascular invasion (P = 0.024), tumour differentiation (P = 0.014), tumour size (P = 0.002), and portal vein tumour thrombus (PVTT) (P = 0.028). Cell proliferation, colony formation and migration in vitro were enhanced by PRMT1 upregulation and decreased by PRMT1 downregulation in HCC cell lines. Moreover, low PRMT1 expression resulted in slow tumour growth and decreased tumour weight in vivo, as well as tumour metastasis. These phenotypes were associated with STAT3 signalling pathway activation. Cryptotanshinone, a STAT3 inhibitor, inhibited STAT3 phosphorylation and reversed the HCC phenotype of PRMT1 expression. Conclusions: We revealed a significant role for PRMT1 in HCC progression and metastasis in vitro and in vivo via STAT3 signalling pathway activation. PRMT1 may be a potential novel prognostic biomarker and new therapeutic target for HCC.

show abstract

miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1

Cited by 62 publications

References 30 publications

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Decreased miR-503 expression in gastric cancer is inversely correlated with serum carcinoembryonic antigen and acts as a potential prognostic and diagnostic biomarker

PRMT1 Promoted HCC Growth and Metastasis In Vitro and In Vivo via Activating the STAT3 Signalling Pathway

Contact Info

Product

Resources

About